DDInter581 DDInter1658
Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Dolasetron {u} (Compound) resembles {v} (Compound) Hyoscyamine
Dolasetron {u} (Compound) resembles {v} (Compound) Atropine
Dolasetron {u} (Compound) binds {v} (Gene) CYP2D6
Dolasetron {u} (Compound) upregulates {v} (Gene) UBQLN2
Dolasetron {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin 3 Receptor Antagonists
Dolasetron {u} (Compound) causes {v} (Side Effect) Oliguria
Dolasetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Dolasetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rifampicin
Dolasetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxycodone
Dolasetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Donepezil
Dolasetron (Compound) resembles Hyoscyamine (Compound)
Dolasetron (Compound) resembles Atropine (Compound)
Dolasetron (Compound) binds CYP2D6 (Gene)
Dolasetron (Compound) upregulates UBQLN2 (Gene)
Dolasetron (Compound) is included by Serotonin 3 Receptor Antagonists (Pharmacologic Class)
Dolasetron (Compound) causes Oliguria (Side Effect)
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Rifampicin
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Donepezil